New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
07:05 EDTDGXQuest Diagnostics plans to sell HemoCue diagnostic products business
Quest Diagnostics announced that it plans to sell its HemoCue diagnostic products business, as part of the company's strategy to refocus on diagnostic information services. HemoCue develops, produces and markets point-of-care testing systems. As a result, Quest Diagnostics will report 2012 and 2011 results for HemoCue and its OralDNA products business, which was sold in December, 2012, as discontinued operations in its report of fourth quarter 2012 results, and take related after-tax charges in discontinued operations for the estimated asset impairment associated with HemoCue and the loss on sale associated with OralDNA, totaling $89.5M, or 56c per diluted share, in the period. The company's consolidated income statements for FY12 and 2011 will present the operating results of HemoCue and OralDNA as discontinued operations. As such, results from continuing operations will be reduced as follows: Revenues by $117M in 2012 and $119M in 2011; Operating income by $11M in 2012 and $8M in 2011; Net income from continuing operations by $15M in 2012 and $13M in 2011; and EPS by 9c in 2012 and 8c in 2011.
News For DGX From The Last 14 Days
Check below for free stories on DGX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
07:05 EDTDGXQuest Diagnostics narrows 2014 adjusted EPS view to $4.00-$4.10 from $3.95-$4.15
Subscribe for More Information
07:02 EDTDGXQuest Diagnostics reports Q2 adjusted EPS $1.08, consensus $1.06
Subscribe for More Information
July 22, 2014
07:08 EDTDGXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use